Edgewise Therapeutics

Yahoo Finance • 2 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX).  Such investors are advised to contact Danielle Peyton... Full story

Yahoo Finance • 2 months ago

Edgewise Therapeutics CSO sells $25,539 in EWTX stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Chief Scientific Officer Alan J. Russell, sold 1,907 shares of common stock on August 12, 2025, for approximately $25,539. The shares were sold at an average price of $13.3924, with individual sale... Full story

Yahoo Finance • 2 months ago

Edgewise Therapeutics CFO sells $19k in shares

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Chief Financial Officer, R Michael Carruthers, sold 1,428 shares of common stock on August 12, 2025, at prices ranging from $13.36 to $13.49, realizing approximately $19,124. The transaction comes... Full story

Yahoo Finance • 2 months ago

Edgewise Therapeutics CBO sells shares worth $33,360

Behrad Derakhshan, Chief Business Officer of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), sold 2,491 shares of common stock on August 12, 2025, at prices ranging from $13.36 to $13.49, for a total value of $33,360. The transaction comes as t... Full story

Yahoo Finance • 2 months ago

Edgewise Therapeutics general counsel sells $28k in shares

Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a $1.47 billion market cap biotech company, saw its General Counsel John R. Moore sell 2,098 shares of common stock on August 12, 2025, at an average price of $13.3924, for a total value of $28,09... Full story

Yahoo Finance • 2 months ago

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Edgewise Therapeutics, Inc. (“Edgewise Therapeutics” or “the Company”)... Full story

Yahoo Finance • 2 months ago

Edgewise Therapeutics GAAP EPS of -$0.34

* Edgewise Therapeutics press release [https://seekingalpha.com/pr/20191827-edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules] (NASDAQ:EWTX [https://seekingalpha.com/symbol/EWTX]): Q2 GAAP EPS of -$... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX).  Such investors are advised to contact Danielle Peyton... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton a... Full story

Yahoo Finance • 4 months ago

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

Wedbush analyst Laura Chico lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated f... Full story

Yahoo Finance • 4 months ago

RBC Capital reiterates outperform rating on Edgewise stock amid BMD progress

Investing.com - RBC Capital maintained its Outperform rating and $48.00 price target on Edgewise Therapeutics (NASDAQ:EWTX) stock on Friday, highlighting the company’s progress with its sevasemten drug candidate. The $1.39 billion market... Full story

Yahoo Finance • 4 months ago

Edgewise reports positive results for muscular dystrophy drug

BOULDER, Colo. - Edgewise Therapeutics (NASDAQ:EWTX), a $1.52 billion market cap biotech company with a robust financial position and more cash than debt, announced Thursday that its experimental drug sevasemten showed sustained disease st... Full story

Yahoo Finance • 5 months ago

Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential?

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other top small cap stocks to buy... Full story

Yahoo Finance • 6 months ago

Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other unstoppable stocks that could double y... Full story

Yahoo Finance • 2 years ago

11 Cheap Small-Cap Stocks to Buy Before the Next Breakout

In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap stocks and the latest events in the stock market, then take a look at 5 Cheap Small-Ca... Full story